Clinical Aspects of Hemodialysis Biocompatibility

  • Alfred K. Cheung
Part of the Developments in Nephrology book series (DINE, volume 24)


Bioincompatibility of the hemodialysis extracorporeal circuit occurs primarily through one of several mechanisms: (a) cell adhesion, aggregation and activation; (b) transformation and adsorption of noncellular elements such as proteins; (c) mechanical shear; and (d) leaching and spallation of substances (1). Many substances are produced in the hemodialysis circuit which have theoretical biological effects. Whether these substances in fact lead to the theoretical effects, however, depend on a number of other factors: the timing and location of the production of the substances as well as the thresholds for the potential consequential events.


Dialysis Patient Hemodialysis Patient Complement Activation Ethylene Oxide Cellulosic Dialysis Membrane 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Leonard EF: Dialysis membranes. Proc Eur Dial Transplant Assoc 21:99–109, 1984.Google Scholar
  2. 2.
    Zusman RM, Rubin RH, Cato AE, Cocchetto DM, Crow JW, Tolkoff-Rubin N. Hemodialysis using prostacyclin instead of heparin as the sole antithrombotic agent. N Engl J Med 304: 934–939, 1981.PubMedCrossRefGoogle Scholar
  3. 3.
    Simon P, Ang KS, Cam G: Enhanced platelet aggregation and membrane biocompatibility: possible influence on thrombosis and embolism in hemodialysis patients. Nephron 45: 172–173, 1987.PubMedCrossRefGoogle Scholar
  4. 4.
    Chenoweth DE, Cheung AK, Henderson LW: Anaphylatoxin formation during hemodialysis: Effects of different dialyzer membranes. Kidney Int 24:764–769, 1983.PubMedCrossRefGoogle Scholar
  5. 5.
    Cheung AK, Henderson LW: Effects of complement activation by hemodialysis membranes. Am. J. Nephrol. 6: 81–91, 1986.PubMedCrossRefGoogle Scholar
  6. 6.
    DeBacker WA, Verpooten GA, Borgonjon DJ, Vermeire PA, Lins RR, DeBroe ME: Hypoxemia during hemodialysis: effects of different membranes and dialysate compositions. Kidney Int 23: 738–743, 1983.CrossRefGoogle Scholar
  7. 7.
    Camussi G, Pacitti A, Tetta C, Bellone G, Mangiarotti G, Canavese C, Segoloni G, Vercellone A: Mechanisms of neutropenia in hemodialysis (HD). Trans Am Soc Artif Intern Organs 30: 364–368, 1984.PubMedGoogle Scholar
  8. 8.
    Chenoweth DE, Cheung AK, Ward DM, Henderson LW: Anaphylatoxin in formation during hemodialysis: Comparison of new and re-used dialyzers. Kidney Int 24: 770–774, 1983.PubMedCrossRefGoogle Scholar
  9. 9.
    Kay NE, Raij LR: Immune abnormalities in renal failure in hemodialysis. Blood Purification 4: 120–129, 1986.PubMedCrossRefGoogle Scholar
  10. 10.
    Luger A, Kovarik J, Stummvoll H-K, Urbanska A, Luger TA: Blood-membrane interaction in hemodialysis leads to increased cytokine production. Kidney Int 32: 84–88, 1987.PubMedCrossRefGoogle Scholar
  11. 11.
    Gejyo F, Odani S, Yamada T, et al: ß2-microglobulin: a new form of amyloid proteins associated with chronic hemodialysis. Kidney Int 30: 385–390, 1986.PubMedCrossRefGoogle Scholar
  12. 12.
    Bommer J, Ritz E: Spallation of dialysis materials: problems and perspectives. Nephron 39:285–289, 1985.PubMedCrossRefGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1989

Authors and Affiliations

  • Alfred K. Cheung
    • 1
    • 2
  1. 1.Renal SectionVeterans Administration Medical CenterSalt Lake CityUSA
  2. 2.The Department of MedicineUniversity of Utah School of MedicineSalt Lake CityUSA

Personalised recommendations